PHARMAXIS ENROLLS FIRST PATIENT IN BRONCHIECTASIS TRIAL
Pharmaxis has reported that the first of 350 patients has enrolled in its Phase III Bronchitol trial to treat the chronic obstructive lung disease, bronchiectasis; an incurable, degenerative and chronic inflammatory condition of the lungs affecting more than half a million people worldwide.
The trial will investigate the safety and effectiveness of Bronchitol in the treatment of bronchiectasis. It is being conducted at 22 hospitals across Australia, New Zealand, the UK and Northern Ireland. Two thirds of trial volunteers will receive Bronchitol and the remaining one third will receive a placebo. Patients will be assessed for mucus clearance and quality of life as measured by symptoms, cough severity, exercise capacity and lung function.